Loading...
Loading...
KYMR| Name | Value |
|---|---|
| Revenues | 25.6M |
| Cost of Revenue | 1.9M |
| Gross Profit | 23.8M |
| Operating Expense | 74.7M |
| Operating I/L | -50.9M |
| Other Income/Expense | 8.9M |
| Interest Income | 8.9M |
| Pretax | -42.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -42.1M |
Kymera Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of small molecule therapeutics that target disease-causing proteins for degradation. The company's focus is on harnessing the body's natural protein degradation system to develop treatments for immunology-inflammation diseases, hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. Kymera's pipeline includes programs targeting IRAK4, MYD88-mutated diffuse large B cell lymphoma, STAT3, and MDM2 for various disease indications. By advancing these programs through clinical trials and potential commercialization, Kymera aims to generate revenue through the sale of its novel small molecule therapeutics.
